SG Americas Securities LLC acquired a new stake in Unity Biotechnology Inc (NASDAQ:UBX) during the first quarter, HoldingsChannel reports. The fund acquired 12,992 shares of the company’s stock, valued at approximately $105,000.
Other large investors have also recently made changes to their positions in the company. Legal & General Group Plc boosted its holdings in shares of Unity Biotechnology by 416.4% in the 4th quarter. Legal & General Group Plc now owns 3,863 shares of the company’s stock valued at $63,000 after buying an additional 3,115 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Unity Biotechnology by 40.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 15,705 shares of the company’s stock valued at $256,000 after buying an additional 4,532 shares in the last quarter. Citigroup Inc. boosted its holdings in shares of Unity Biotechnology by 374.7% in the 4th quarter. Citigroup Inc. now owns 6,589 shares of the company’s stock valued at $107,000 after buying an additional 5,201 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in shares of Unity Biotechnology by 5,850.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 5,355 shares of the company’s stock valued at $43,000 after buying an additional 5,265 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY acquired a new position in shares of Unity Biotechnology in the 4th quarter valued at $144,000. 38.21% of the stock is currently owned by institutional investors.
Several brokerages have recently issued reports on UBX. Zacks Investment Research upgraded shares of Unity Biotechnology from a “sell” rating to a “hold” rating and set a $10.00 target price for the company in a report on Tuesday, May 14th. Cantor Fitzgerald began coverage on shares of Unity Biotechnology in a report on Wednesday, March 6th. They issued an “overweight” rating and a $21.00 target price for the company. Finally, Mizuho restated a “buy” rating on shares of Unity Biotechnology in a report on Wednesday, March 6th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $22.00.
Shares of NASDAQ:UBX opened at $8.40 on Thursday. Unity Biotechnology Inc has a 1-year low of $7.39 and a 1-year high of $24.56.
Unity Biotechnology (NASDAQ:UBX) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.03. Analysts forecast that Unity Biotechnology Inc will post -1.91 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “SG Americas Securities LLC Acquires New Stake in Unity Biotechnology Inc (NASDAQ:UBX)” was first reported by Macon Daily and is the property of of Macon Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://macondaily.com/2019/06/13/sg-americas-securities-llc-acquires-new-stake-in-unity-biotechnology-inc-nasdaqubx.html.
Unity Biotechnology Profile
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.
See Also: Dividend Achievers
Want to see what other hedge funds are holding UBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unity Biotechnology Inc (NASDAQ:UBX).
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.